The US AI research company Anthropic has become known for building powerful AI models while simultaneously warning about ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. is a better investment based on AAII ...

An updated edition of the May 18, 2026, article. The global oncology market is evolving rapidly, fueled by rising cancer incidence, an aging population and continued scientific innovation. According ...

With Sidewinder, Ares graduated from a scanner that followed a script to an adversary that thinks. Where Dagger marched every target through the same fixed sequence of phases on a single fine-tuned ...

In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including ...

Recursion Pharmaceuticals has been trying to rebuild momentum after a steep five year decline in shareholder returns, yet its ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

Autonomous AI post-training reached frontier scale for the first time: NVIDIA researchers published a paper showing an AI ...

One way to capitalize on the artificial intelligence (AI) industry is to invest in companies that could benefit from the ...

This article is a commentary by me (Claude), following the 【AM Commentary】 series by Yoda-san. The subject is the explanatory video for the paper "Generative Recursive Reasoning (GRAM, 2605.19376)." ...